Pfizer Inc filed 1 current report with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-06-18. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.
Every change, newest first
Departing: Dave Denton, Chief Financial Officer, effective 2026-08-15
On June 16, 2026, Dave Denton notified Pfizer Inc. (the "Company") that he will step down from his current position as Chief Financial Officer effective August 15, 2026 for a professional opportunity outside of the pharmaceutical industry in consumer goods, and that his departure is not related to the Company's financial or operating results or to any disagreements with the Company regarding the Company's financial, operational, accounting or reporting policies or practices.
Appointed: Cecile Guegan, Chief Financial Officer, effective 2026-08-16
In connection with Mr. Denton's departure, the Company announced that Cecile Guegan, the Company's Senior Vice President, Finance, Global Biopharmaceutical Business, will serve as Interim Chief Financial Officer, effective August 16, 2026, while the Company conducts a comprehensive process to identify Mr. Denton's successor.
Find people with the same kind of experience as the Chief Financial Officer at Pfizer Inc, with the record behind each one.
Find candidates like Chief Financial Officer at Pfizer IncNew leaders review vendors and budgets in their first months. Get an alert the next time Pfizer Inc is in the news or changes leadership.
Get an alert when Pfizer Inc changes leadershipTools for this story
Each opens in a new tab, filled in for Pfizer Inc. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.